Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?

Key Takeaways Novo Nordisk cuts 2025 outlook, primarily due to weaker uptake of Wegovy in obesity markets.Alhemo wins EU approval for hemophilia A and B with inhibitors, adding to NVO's rare disease portfolio.Wegovy gains FDA nod for MASH, becoming the first GLP-1 therapy approved for liver disease treatment.Novo Nordisk (NVO) suffered a major setback in July after slashing its 2025 sales and profit outlook, triggering a decline in its share price. The downgrade reflects slower-than-expected momentum for it ...